Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2022-03-23 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
Cleansing Notice under S708A(5)(e) Corporations Act 1
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 regarding the issuance of shares upon exercise of options. It references an Appendix 2A and confirms compliance with disclosure requirements. The content is a regulatory announcement about share issuance and compliance, not a full financial report or detailed filing. The document length is short (1358 characters), and it serves as a formal notification rather than a report or detailed financial statement. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-03-23 English
Development of Glioblastoma Therapy Program 3 pages 235.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing progress in the clinical development of a glioblastoma therapy program by Telix Pharmaceuticals. It discusses clinical trial phases, approvals, and study details but does not contain financial statements, earnings data, or detailed financial analysis. It is a corporate announcement about research and development progress rather than a financial report or regulatory filing. The document length is 8380 characters, which is substantial but the content is clearly an operational update on clinical development. Therefore, it fits best under the category of a general regulatory announcement or corporate update rather than a financial report or management discussion. The most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-03-22 English
Radiopharmaceutical Production Facility Buildout Commences 3 pages 239.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release titled 'Telix Radiopharmaceutical Production Facility Buildout Commences' dated 22 March 2022. It provides a detailed update on the company's capital expenditure plans, financing arrangements, and strategic objectives related to the buildout of a new production facility. The content focuses on financing details, project stages, loan terms, and government grants, which are typical of a capital or financing update. There are no financial statements, quarterly or annual results, or management discussion of financial performance. The document is not a report itself but an announcement of a material update related to financing and capital expenditure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (9293 characters) supports it being a substantive announcement rather than a brief notice or report publication announcement.
2022-03-21 English
Application for quotation of securities - TLX 9 pages 35.1KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Telix Pharmaceuticals Limited. It details the issuance and conversion of options and warrants into ordinary fully paid shares, including numbers, issue dates, exercise prices, and whether the securities are quoted or unquoted. The document is a regulatory announcement related to securities issuance and quotation, not a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but is a formal notification to the exchange about securities to be quoted. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2022-03-13 English
Cleansing Notice under S708A(5)(e) Corporations Act 1
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001, relating to the issuance of shares upon exercise of options and warrants. It references compliance with disclosure provisions and confirms no excluded information is present. The document is short (1371 characters) and serves as a regulatory announcement about share issuance without detailed financial data or report content. This fits the category of a Regulatory Filing (RNS) rather than a full financial report or capital change announcement, as it is a formal compliance notice under securities law.
2022-03-13 English
Notice Required Under ASX Listing Rule 3.13.1 1 pag
AGM Information Classification · 95% confidence The document is an ASX release from Telix Pharmaceuticals Limited dated 10 March 2022. It announces the intention to hold the Annual General Meeting (AGM) on 18 May 2022 and provides details about the nomination deadline for director elections. It states that further details and the notice of meeting will be provided later. The document does not contain the actual AGM materials or presentations but is a notice related to the AGM. The document length is 2757 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as AGM Information (AGM-R), as it relates to the AGM but is not the full report or materials themselves.
2022-03-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.